Zuellig Pharma
Concise Prescribing Info
Topotecan HCl
Metastatic ovarian carcinoma after failure of initial or subsequent chemotherapy; small cell lung cancer sensitive disease after failure of 1st-line chemotherapy. In combination w/ cisplatin for the treatment of histologically confirmed stage IV-B, recurrent or persistent carcinoma of the cervix.
Dosage/Direction for Use
Ovarian & small cell lung carcinoma 1.5 mg/m2 by IV infusion over 30 min daily for 5 consecutive days, starting on day 1 of a 21-day course. A min of 4 courses is recommended. In the event of severe neutropenia during any course, reduce dose by 0.25 mg/m2 for subsequent courses. Alternatively, G-CSF may be given following the subsequent courses (before resorting to dose reduction) starting from day 6, 24 hr after the completion of topotecan administration. Cervical cancer Initial dose: 0.75 mg/m2 by IV infusion over 30 min daily on days 1, 2 & 3. Administer cisplatin IV infusion 50 mg/m2 on day 1 & following topotecan dose. Repeat every 21 days for 6 courses or until progressive disease.
Hypersensitivity. Severe bone marrow depression as evidenced by baseline neutrophil count <1.5 x 109/L &/or platelet count ≤100 x 109/L. Pregnancy & lactation.
Special Precautions
Monitor full blood count including platelets regularly. Myelosuppression, neutropenia which can cause neutropenic colitis. History of interstitial lung disease (ILD), pulmonary fibrosis, lung cancer, thoracic exposure to radiation & use of pneumotoxic drugs &/or colony-stimulating factors; monitor for pulmonary symptoms of ILD eg, cough, fever, dyspnoea, &/or hypoxia. Discontinue in case of new diagnosis of ILD. Diarrhoea. May impair ability to drive or operate machinery.
Adverse Reactions
Infection, anaemia, febrile neutropenia, leucopenia, neutropenia, thrombocytopenia, anorexia, diarrhoea, nausea & vomiting, abdominal pain, constipation, stomatitis, alopecia, asthenia, fatigue, pyrexia.
Drug Interactions
Greater myelosuppression w/ other cytotoxic agents (eg, paclitaxel or etoposide) & platinum-containing agents (eg, cisplatin or carboplatin). Duration of neutropenia prolonged by G-CSF.
ATC Classification
L01XX17 - topotecan ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Hycamtin infusion 4 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in